InBody Scholar

InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition.
With our long history in the industry, we provide more than 6,000 research and publications.
Research title with ★ indicates InBody recommended paper.

Safety and efficacy of long‐term tolvaptan therapy for decompensated liver cirrhosis

Kogiso T et al.
Used Parameters : ECW/TBW, Protein

Publication Year : 2015

Country : Japan

Journal : Hepatology Research

Aim Recently, the short‐term efficacy of the vasopressin V2 receptor antagonist tolvaptan for the treatment of ascites in cirrhosis was reported. However, the long‐term effects remain unknown. Here, we report the clinical features of decompensated cirrhosis treated using long‐term tolvaptan therapy, and evaluate its safety and efficacy. Methods Fifty‐five cirrhotic patients hospitalized due to ascites, despite receiving appropriate diuretic treatment, were treated with tolvaptan. We excluded 35 patients due to liver transplant (20.0%), death …
Full text